v3.26.1
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2025
Shareholders' Equity [Abstract]  
Schedule of Information Regarding Outstanding Warrants to Purchase Shares

The following table summarizes information regarding outstanding warrants to purchase the Company’s ordinary shares as of December 31, 2025:

 

Issuance date  Number of
outstanding
Warrants
   Exercise
price per
warrant
 
         
December 2021   3,500   $200.0 
January 2023 agent   9,545   $68.75 
November 2023   243,377   $17.50 
November 2023 agent   13,746   $19.13 
August 2024   571,429   $22.50 
August 2024 agent   20,000   $21.90 
April 2025   17,500   $15.0 
July 2025   1,666,667   $4.67 
July 2025   58,333   $7.50 
    2,604,097      
Schedule of Company's Option Activity

The following table summarizes Company’s option activity during the year ended December 31, 2025: 

 

   Number of
options
   Weighted
average
exercise
price
   Weighted
average
remaining
contractual
terms
(in years)
   Aggregate
intrinsic
value
 
                 
Outstanding at December 31, 2024   41,610    90    7.1    - 
Grants   8,000    16.01    10    - 
Forfeited/expired   (77)   -    -         - 
                     
Outstanding at December 31, 2025   49,533    87.31    6.6    - 
                     
Vested and expected to vest at December 31, 2025   49,533    87.31    6.6    - 
                     
Exercisable at December 31, 2025   25,497    143.98    5.7    - 
Schedule of Fair value of Company’s Share Options Granted

The fair value of the Company’s share options granted was estimated using the binomial option pricing model using the following range assumptions:

 

Description   2025   2024   2023
             
Risk-free interest rate   4.04%-4.21%   4.64%-5.09%   3.95%-3.96%
Expected volatility   79.56%-79.82%   83.40%-83.94%   84.30%-84.76%
Dividend yield   0%   0%   0%
Contractual life (in years)   10   9.75-10   10
Early Exercise Multiple (Suboptimal Factor)   2.5   2.5   2.5
Schedule of Expenses Recognized Financial Statements Expenses recognized in the financial statements:

 

   Year ended December 31, 
   2025   2024   2023 
             
Research and development  $57   $75   $83 
General and administrative (*)   283    287    178 
    340    362    261 

 

(*)Including $141 and $112 share based compensation for services provided in 2025 and 2024, refer to note 9(b)(6) and note 9(b)(1), respectively.